The results of this study showed that the CD4+ and CD4/CD8 ratios of the experimental group were higher than those of the control group, and the CD8+ level was lower than that of the control group (P < 0.05), suggesting that mesalazine plus somatostatin and bifidus triple capsules can effectively regulate T cell frequency of ulcerative colitis patients. This evidence concerns the gene CD4 and ulcerative colitis.